Navigation Links
The Apollo Posterior Stabilized Knee System

ProductsThe Apollo Posterior Stabilized Knee System
Company Zimmer, Inc.
Item The Apollo Posterior Stabilized Knee System
Features PCL retaining, sacrificing and substituting components. A choice of porous or nonporous femoral components. All polyethylene or baseplate/insert tibial components. A range of elliptical all-polyethylene patellae.
Description Maximum contact. Minimum wear. Outstanding results.
Info Zimmer, Inc.
Customer Service: (800) 613-6131

Related medicine products :

1. The Apollo Primary Knee System
2. The Apollo Knee System
3. The Apollo Hip System
4. Apollo
5. Holladay Posterior Capsule Polisher and Curette
6. Posterior Capsule Polisher, 23 g
7. Posterior Capsule Polisher, 21 g
8. Simcoe Posterior Chamber Lens Forceps
9. Spine-Tract Posterior Lumbar Retractor System
10. Image-Trac Posterior Spine Retractor System
11. Graftech Posterior Ramp
Breaking Medicine Technology:Within3 Expands into Mobile Applications 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2Cardiac Science Appoints Healthcare Executive Ronald A Andrews Jr to Board of Directors 6032 1Cardiac Science Appoints Healthcare Executive Ronald A Andrews Jr to Board of Directors 6032 2Cardiac Science Appoints Healthcare Executive Ronald A Andrews Jr to Board of Directors 6032 3Cardiac Science Appoints Healthcare Executive Ronald A Andrews Jr to Board of Directors 6032 4Cardiac Science Appoints Healthcare Executive Ronald A Andrews Jr to Board of Directors 6032 5InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 1InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 2InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 3InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 4InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 5InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 6InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 7InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 8InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 9InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 10InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 11InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 12InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 13Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results 6022 1Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results 6022 2Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results 6022 3Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results 6022 4Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results 6022 5Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results 6022 6Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results 6022 7